Planning

NHS NOFE and Midlands & East Branded Medicines - Tranche A- 1 September 2026

  • NHS England

UK2: Preliminary market engagement notice - Procurement Act 2023 - view information about notice types

Notice identifier: 2026/S 000-002508

Procurement identifier (OCID): ocds-h6vhtk-051c98 (view related notices)

Published 13 January 2026, 9:57am



Scope

Reference

C414060

Description

NHS Branded Framework Agreement – Lot 1 - Tranche A for the North of England and Midlands & East.

Period of Framework Agreement: 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months.

Lot 2 - Natalizumab for London and South of England. The period of Framework Agreement : 1st September 2026 to 31st August 2027 with an option or option(s) to extend for a further 12 months.

Commercial tool

Establishes a framework

Total value (estimated)

  • £456,000,000 excluding VAT
  • £547,200,000 including VAT

Above the relevant threshold

Contract dates (estimated)

  • 1 September 2026 to 31 August 2028
  • Possible extension to 31 August 2030
  • 4 years

Main procurement category

Goods

CPV classifications

  • 33600000 - Pharmaceutical products

Contract locations

  • UKC - North East (England)
  • UKD - North West (England)
  • UKF - East Midlands (England)
  • UKG - West Midlands (England)
  • UKH - East of England
  • UKI - London
  • UKK - South West (England)
  • UKJ - South East (England)

Engagement

Engagement deadline

27 January 2026

Engagement process description

NHS England is advising suppliers of an upcoming tender for the NHS Branded Framework Agreement – Tranche A for the North of England and Midlands & East.

Period of Framework Agreement (Lot 1): 1st September 2026 to 31st August 2028 with an option or option(s) to extend (at the authority’s discretion for a further 24 months.

There will be a separate Lot to provide framework agreement coverage to the London and South of England regions for Natalizumab. The period of Framework Agreement (Lot 2): 1st September 2026 to 31st August 2027 with the option or option(s) to extend for a further 12 months.

Eight category areas are covered in Tranche A: Erythropoietin Stimulating Agents, Granulocyte-Colony Stimulating Factor (GCSF), Insulin Analogues, MS Drugs, Parenteral Iron, Severe Asthma, Severe Asthma/Interleukin Inhibitor and Teriparatide.

The purpose of this notice is to inform existing and potential new suppliers that if NHS England believe that it would be beneficial a virtual 1:1 preliminary market meeting can be arranged.  Please contact ian.birch1@nhs.net to register your interest. There will also be a 14 day window for queries to be raised via Atamis after all sessions have concluded.


Participation

Particular suitability

Small and medium-sized enterprises (SME)


Submission

Publication date of tender notice (estimated)

9 March 2026


Contracting authority

NHS England

  • Public Procurement Organisation Number: PDPT-3135-BWWY

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

United Kingdom

Region: UKI45 - Lambeth

Organisation type: Public authority - central government